New 52-week analyses from the phase 3 SOL-1 trial suggest that the investigational intravitreal therapy AXPAXLI (OTX-TKI) may ...
Glaukos Corporation announced that the US Centers for Medicare and Medicaid Services (CMS) has assigned a permanent ...
Gabriel discusses a robotic femtosecond laser platform for LASIK, focusing on flap accuracy, stromal bed precision, and the ...
Uncorrected acuity at 36 months showed continuous range: monocular 20/20 distance and intermediate, 20/27 near; binocular ...
For cataract surgeons, the conversation around phacoemulsification is increasingly shifting from ultrasound power to fluidics ...
The management of dry eye disease may benefit from earlier intervention, according to data presented by Eric D. Donnenfeld, ...
On March 9, 2026, SpyGlass Pharma announced positive 12-month results from its phase 1/2 trial of the Bimatoprost Drug ...
Motugivatrep introduces first-in-class topical TRPV1 antagonism for DED, targeting corneal nociceptor-driven discomfort ...
An ophthalmology resident shares insights from experiences across Mexico, Europe, and the US.
Unmet need persists for globe-sparing retinoblastoma therapy that does not depend on intra-arterial chemotherapy ...
Tran, MD, compared refractive accuracy, cylinder correction, and postoperative adjustment rates between femtosecond ...
The importance of experience becomes apparent early in medical training. Yet experience is shaped not only by time—it is also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results